Clinical Trial Search

Primary: Change From Baseline to Week 12 in Weekly Average Pain Intensity (wAPI) — 0.14; -0.22 units on a scale — p=0.134

Primary: Overall Survival (OS) — 237; 323 days — p== 0.000017

Primary: Incidence of Treatment-emergent Adverse Events — 182 Participants

Primary: Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency — 22.8; 20.0; 20.2; 19.2 percentage of participants

Primary: Participants With Adverse Events — 4; 2; 34; 25 Participants

Primary: Hamilton Rating Scale for Depression-17 Item — 19.0; 19.9; 19.4; 13.9 units on a scale — p=.95

Primary: Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. — -1.44; -1.91; -1.28 Percentage of glycosylated haemoglobin

Primary: Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 — 123; 139; 34; 31 Participants — p=0.238

Primary: Incidence of Hearing Loss — 14; 31 Patients

Primary: Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling — -5.4; 1.2 Percent Change

Primary: Complete Response (CR) and Complete Response Unconfirmed (CRu) — 20.0; 5.7; 24.3; 7.1 percentage of randomized patients

Primary: Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear — 1.04; 1.02; 2.78; 11.22 Percentage of superficial cells

Primary: Duration of Post-operative Delirium — 3.3; 3.1 days

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Reported in the Double Blind (DB) + Open Label (OL) Period. — 177; 5; 91; 151 participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 95.3 percentage of participants